The estimated Net Worth of Jonathan Poole is at least $42.3 Tisíc dollars as of 24 July 2017. Jonathan Poole owns over 45,000 units of Evelo Biosciences Inc stock worth over $1,896 and over the last 11 years Jonathan sold EVLO stock worth over $40,447.
Jonathan has made over 4 trades of the Evelo Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Jonathan exercised 45,000 units of EVLO stock worth $139,050 on 24 July 2017.
The largest trade Jonathan's ever made was exercising 45,000 units of Evelo Biosciences Inc stock on 24 July 2017 worth over $139,050. On average, Jonathan trades about 5,184 units every 37 days since 2014. As of 24 July 2017 Jonathan still owns at least 84,247 units of Evelo Biosciences Inc stock.
You can see the complete history of Jonathan Poole stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan a Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: